Code Bio is a company developing precision genetic medicines to treat life-threatening diseases. The company leverages its proprietary synthetic DNA delivery platform, 3DNA®, to overcome challenges in genetic medicine delivery.

Code Bio

Code Bio was founded on the belief that more can be done for people living with debilitating genetic diseases. We are driven by the potential of our transformative technology to deliver precision genetic medicines for patients.

Code Bio leverages its proprietary, novel, multivalent, synthetic DNA delivery platform, 3DNA®, which has been engineered to overcome many of the challenges inherent with delivery of genetic medicines, such as: dose related toxicity, off-target effects, immunogenicity, gene size and delivery limitations, bioavailability, ability to re-dose, and vector manufacturing complexity.

The Company is advancing an internal pipeline focusing on a variety of diseases with its most advanced research in Duchenne’s Muscular Dystrophy (DMD). Code Bio also has research programs underway based on targeting data focused on the lungs, pancreas, and liver.

New Enterprise Associates

CureDuchenne Ventures

4BIO Capital

Takeda Ventures

UPMC Enterprises

JDRF T1D Fund

Northpond Ventures

Amgen Ventures

Hatteras Venture Partners

UCB Ventures

Code Biotherapeutics

Looking forward to moderating a panel at the Longwood Healthcare Leaders conference next week discussing Pipeline Positioning with an exceptional group of biotech CEO panelists including Brendan Smith, CEO of Doppler Bio, Joanne Smith-Farrell, CEO of Be Bio, Lara S. Sullivan, M.D., CEO of Pyxis Oncology, and Ming Wang, CEO of Phanes Therapeutics.

Our Chief Scientific Officer, David Anderson, and Chief Business Officer, Lauren Kaskiel represented Code Bio at the European Society of Gene and Cell Therapy 30th Annual Congress! Check out these behind-the-scenes snapshots as they #network, learn, and collaborate with industry leaders. #ESGCT

We’re thrilled to be attending the J.P. Morgan Healthcare Conference in a few weeks! We are looking forward to sharing our progress in developing our novel non-viral 3DNA platform and pipeline that overcomes current #geneticmedicine delivery challenges. See you there! #JPM24

Our Chief Scientific Officer, David Anderson, is presenting for Code Bio at Chardan 's 7th Annual Genetic Medicines Conference. This conference highlights genetic medicines through featured fireside chats, presentations, panel discussions and spotlights perspectives from groundbreaking thought leaders: https://bit.ly/3LIc7zl

#CGMC2023 #ChardanGMConf

Our Chief Scientific Officer, David Anderson, Ph.D., will be presenting at the Oppenheimer & Co. Inc. 34th Annual #Healthcare Life Sciences Conference on February 14. We’re excited to connect with #investors to showcase the strides Code Bio is making as we advance a new class of precision #geneticmedicine. Learn more: https://bit.ly/3SnWwYc #OPCOLifeSciences

Our CEO, Brian McVeigh will be sharing his experience at the Goodwin & KPMG US 5th Annual Symposium during the J.P. Morgan Healthcare Conference. Learn more: https://bit.ly/3Rv4MXl #JPM24

news_impact_assignment_basic

key_people

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

merger_acquisitions

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	Aug 23, 2024 8:30 PM	82e16da6
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general
crunchbase trigger	general
crunchbase profile	general
li profile	general	Aug 23, 2024 8:30 PM	3f875578
translate crunchbase fundingrounds	general
peers	general	Aug 23, 2024 8:30 PM	80aa1e71
news basic	general	Aug 23, 2024 8:30 PM	96f99851
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

CODE

COM:CODEBIOTX

Code Bio